Poster 29
Jun 6, 2023
1 min read
Efficacy and Safety of Amlitelimab, a Nondepleting Anti-OX40 Ligand Antibody, in Combination With Topical Therapy in Participants With Moderate-to-Severe Atopic Dermatitis: 24-Week Results From the SHORE Phase 3 Trial
Eric Simpson, Stephan Weidinger, Michael Cameron, Thomas Hubiche, Xinghua Gao, Yoko Kataoka, Guy Gherardi, Pei Li, Karl Yen, Charlotte Bernigaud, Sonya Davey


